563 related articles for article (PubMed ID: 15308697)
21. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
Yi CE; Ba L; Zhang L; Ho DD; Chen Z
J Virol; 2005 Sep; 79(18):11638-46. PubMed ID: 16140741
[TBL] [Abstract][Full Text] [Related]
22. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
[TBL] [Abstract][Full Text] [Related]
23. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression.
Nie Y; Wang P; Shi X; Wang G; Chen J; Zheng A; Wang W; Wang Z; Qu X; Luo M; Tan L; Song X; Yin X; Chen J; Ding M; Deng H
Biochem Biophys Res Commun; 2004 Sep; 321(4):994-1000. PubMed ID: 15358126
[TBL] [Abstract][Full Text] [Related]
24. [Development and application of a safe SARS-CoV neutralization assay based on lentiviral vectors pseudotyped with SARS-CoV spike protein].
Yan KX; Tan WJ; Zhang XM; Wang HJ; Li Y; Ruan L
Bing Du Xue Bao; 2007 Nov; 23(6):440-6. PubMed ID: 18092680
[TBL] [Abstract][Full Text] [Related]
25. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity difference between the SARS coronavirus and the bat SARS-like coronavirus spike (S) proteins.
Zhou P; Han Z; Wang LF; Shi Z
Biochem Biophys Res Commun; 2009 Sep; 387(2):326-9. PubMed ID: 19595990
[TBL] [Abstract][Full Text] [Related]
27. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
Kapadia SU; Simon ID; Rose JK
Virology; 2008 Jun; 376(1):165-72. PubMed ID: 18396306
[TBL] [Abstract][Full Text] [Related]
28. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein.
Fukushi S; Mizutani T; Saijo M; Matsuyama S; Miyajima N; Taguchi F; Itamura S; Kurane I; Morikawa S
J Gen Virol; 2005 Aug; 86(Pt 8):2269-2274. PubMed ID: 16033974
[TBL] [Abstract][Full Text] [Related]
29. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry.
Simmons G; Reeves JD; Rennekamp AJ; Amberg SM; Piefer AJ; Bates P
Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4240-5. PubMed ID: 15010527
[TBL] [Abstract][Full Text] [Related]
30. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
[TBL] [Abstract][Full Text] [Related]
31. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.
Nie Y; Wang G; Shi X; Zhang H; Qiu Y; He Z; Wang W; Lian G; Yin X; Du L; Ren L; Wang J; He X; Li T; Deng H; Ding M
J Infect Dis; 2004 Sep; 190(6):1119-26. PubMed ID: 15319862
[TBL] [Abstract][Full Text] [Related]
33. Differences in the internalization of self-inactivating VSVG-pseudotyped murine leukemia virus-based vectors in human and murine cells.
Acevedo ML; García-de Gracia F; Miranda-Cárdenas C; Soto-Rifo R; Aguayo F; León O
J Virol Methods; 2018 May; 255():14-22. PubMed ID: 29425681
[TBL] [Abstract][Full Text] [Related]
34. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
[TBL] [Abstract][Full Text] [Related]
35. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.
Shim BS; Stadler K; Nguyen HH; Yun CH; Kim DW; Chang J; Czerkinsky C; Song MK
Virol J; 2012 Sep; 9():215. PubMed ID: 22995185
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
[TBL] [Abstract][Full Text] [Related]
37. The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells.
Wu XD; Shang B; Yang RF; Yu H; Ma ZH; Shen X; Ji YY; Lin Y; Wu YD; Lin GM; Tian L; Gan XQ; Yang S; Jiang WH; Dai EH; Wang XY; Jiang HL; Xie YH; Zhu XL; Pei G; Li L; Wu JR; Sun B
Cell Res; 2004 Oct; 14(5):400-6. PubMed ID: 15450134
[TBL] [Abstract][Full Text] [Related]
38. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor.
Li F; Li W; Farzan M; Harrison SC
Science; 2005 Sep; 309(5742):1864-8. PubMed ID: 16166518
[TBL] [Abstract][Full Text] [Related]
39. Novel immunofluorescence assay using recombinant nucleocapsid-spike fusion protein as antigen to detect antibodies against severe acute respiratory syndrome coronavirus.
He Q; Manopo I; Lu L; Leung BP; Chng HH; Ling AE; Chee LL; Chan SW; Ooi EE; Sin YL; Ang B; Kwang J
Clin Diagn Lab Immunol; 2005 Feb; 12(2):321-8. PubMed ID: 15699428
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.
Hou YX; Peng C; Han ZG; Zhou P; Chen JG; Shi ZL
Virol Sin; 2010 Feb; 25(1):36-44. PubMed ID: 20960282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
